97 related articles for article (PubMed ID: 20699072)
1. [Level of evidence for therapeutic drug monitoring for etoposide after oral administration].
Schieveen PG; Hulin A; Muret P; Royer B;
Therapie; 2010; 65(3):207-12. PubMed ID: 20699072
[TBL] [Abstract][Full Text] [Related]
2. Level of evidence for therapeutic drug monitoring for etoposide after oral administration.
Gerritsen-van Schieveen P; Royer B;
Fundam Clin Pharmacol; 2011 Jun; 25(3):277-82. PubMed ID: 20608987
[TBL] [Abstract][Full Text] [Related]
3. [Not Available].
Schieveen PG; Hulin A; Muret P; Royer B;
Therapie; 2010; 65(3):207-12. PubMed ID: 27392988
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacokinetic aspects of oral administration of etoposide].
Tillmann B; Krümpelmann S; Würthwein G; Wagner A; Schulze-Westhoff P; Hempel G; Jürgens H; Boos J
Klin Padiatr; 1998; 210(4):159-64. PubMed ID: 9743946
[TBL] [Abstract][Full Text] [Related]
5. Clinical and pharmacokinetic study of fractionated doses of oral etoposide in pediatric patients with advanced malignancies.
Gregianin LJ; Brunetto AL; Di Leone L; Costa TD; Santos PP; Schwartsmann G
Med Sci Monit; 2002 Sep; 8(9):PI70-7. PubMed ID: 12218955
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.
Yong WP; Desai AA; Innocenti F; Ramirez J; Shepard D; Kobayashi K; House L; Fleming GF; Vogelzang NJ; Schilsky RL; Ratain MJ
Cancer Chemother Pharmacol; 2007 Nov; 60(6):811-9. PubMed ID: 17308893
[TBL] [Abstract][Full Text] [Related]
7. [Level of evidence for therapeutic drug monitoring for paclitaxel].
Gerritsen-van Schieveen P; Royer B;
Therapie; 2010; 65(3):195-200. PubMed ID: 20699070
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small cell lung cancer.
Miller AA; Tolley EA; Niell HB
Clin Cancer Res; 1998 Jul; 4(7):1705-10. PubMed ID: 9676845
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic optimisation of treatment with oral etoposide.
Toffoli G; Corona G; Basso B; Boiocchi M
Clin Pharmacokinet; 2004; 43(7):441-66. PubMed ID: 15139794
[TBL] [Abstract][Full Text] [Related]
10. The importance of drug scheduling in cancer chemotherapy: etoposide as an example.
Hande KR
Stem Cells; 1996 Jan; 14(1):18-24. PubMed ID: 8820946
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
[TBL] [Abstract][Full Text] [Related]
12. Review of current clinical experience with prolonged (oral) etoposide in cancer treatment.
de Jong RS; Mulder NH; Dijksterhuis D; de Vries EG
Anticancer Res; 1995; 15(5B):2319-30. PubMed ID: 8572646
[TBL] [Abstract][Full Text] [Related]
13. Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration.
Hande K; Messenger M; Wagner J; Krozely M; Kaul S
Clin Cancer Res; 1999 Oct; 5(10):2742-7. PubMed ID: 10537337
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors.
Sonnichsen DS; Ribeiro RC; Luo X; Mathew P; Relling MV
Clin Pharmacol Ther; 1995 Jul; 58(1):99-107. PubMed ID: 7628187
[TBL] [Abstract][Full Text] [Related]
15. [Safe oral administration of etoposide: application to pediatric practice].
Legros MH; Bourget P; Rongeat S; Osmond S; Pein F; Hartmann O
Therapie; 1999; 54(4):487-9. PubMed ID: 10667116
[No Abstract] [Full Text] [Related]
16. Prolonged low doses of oral etoposide may be effective in individual patients with advanced lymphoproliferative disorders refractory to aggressive chemotherapy.
Caruso R; Alesiani F; Latagliata R
Haematologica; 1997; 82(1):126-7. PubMed ID: 9107103
[No Abstract] [Full Text] [Related]
17. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.
Porter D; Boddy A; Thomas H; Lind M; Newell D; Calvert AH; Robson L; Brampton M; Abrahamsen D; Winograd B
Semin Oncol; 1996 Dec; 23(6 Suppl 13):34-44. PubMed ID: 8996574
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma.
Aita P; Robieux I; Sorio R; Tumolo S; Corona G; Cannizzaro R; Colussi AM; Boiocchi M; Toffoli G
Cancer Chemother Pharmacol; 1999; 43(4):287-94. PubMed ID: 10071979
[TBL] [Abstract][Full Text] [Related]
19. Maintenance of long-term remission using oral administration of low-dose etoposide in a patient demonstrating a relapse of blastic natural killer-cell lymphoma.
Hatano Y; Ogata M; Ohishi M; Anan T; Senba K; Yasumatsu T; Katagiri K; Kashima K; Yokoyama S; Kadota JI; Takayasu S; Fujiwara S
Clin Exp Dermatol; 2007 Jan; 32(1):96-7. PubMed ID: 17305910
[No Abstract] [Full Text] [Related]
20. Enhanced bioavailability of etoposide after oral or intravenous administration of etoposide with kaempferol in rats.
Li C; Li X; Choi JS
Arch Pharm Res; 2009 Jan; 32(1):133-8. PubMed ID: 19183886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
